Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamicsClinical data from this trial, ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Keros Therapeutics (KROS) announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results ...

In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics, Inc. (NASDAQ:FBLG) is continuing preparations for a Phase 1/2 trial ...

The company’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of DM-101PX.

The fourth cohort of an ongoing phase 1/2 has dosed its first patient with TTX-MC138 in advanced solid tumors.

- CYT-108 is a recombinant protease inhibitor therapy with potential disease-modifying effects - JUPITER, Fla., April 1, 2025 /PRNewswire/ -- Cytonics, an early-stage biopharmaceutical company ...